

Eleuterio Ferrannini

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3058080/eleuterio-ferrannini-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

337
papers

34,807
citations

82
h-index

184
g-index

357
ext. papers

39,893
ext. citations

8.6
avg, IF

7.28
L-index

#	Paper	IF	Citations
337	Role of anatomical location, cellular phenotype and perfusion of adipose tissue in intermediary metabolism: A narrative review.. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2022 , 23, 43	10.5	1
336	Mannose as a biomarker of coronary artery disease: Angiographic evidence and clinical significance. <i>International Journal of Cardiology</i> , 2022 , 346, 86-92	3.2	1
335	Differential metabolomic signatures of declining renal function in Types 1 and 2 diabetes. <i>Nephrology Dialysis Transplantation</i> , 2021 , 36, 1859-1866	4.3	2
334	Initial combination of metformin, sitagliptin, and empagliflozin in drug-naïve patients with type 2 diabetes: Safety and metabolic effects.. <i>Diabetes, Obesity and Metabolism</i> , 2021 ,	6.7	0
333	Effects of 6 weeks of treatment with dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo-controlled, exploratory study. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1505-1517	6.7	11
332	HDL Containing Apolipoprotein C-III is Associated with Insulin Sensitivity: A Multicenter Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e2928-e2940	5.6	4
331	Response to Comment on Ferrannini and Rosenstock. Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye? <i>Diabetes Care</i> 2021;44:641-646. <i>Diabetes Care</i> , 2021 , 44, e155	14.6	
330	Gamma-glutamyltransferase, arterial remodeling and prehypertension in a healthy population at low cardiometabolic risk. <i>Journal of Human Hypertension</i> , 2021 , 35, 334-342	2.6	
329	Different mechanisms of GIP and GLP-1 action explain their different therapeutic efficacy in type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2021 , 114, 154415	12.7	4
328	Genome-Wide Association Analysis of Pancreatic Beta-Cell Glucose Sensitivity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, 80-90	5.6	2
327	A Journey in Diabetes: From Clinical Physiology to Novel Therapeutics: The 2020 Banting Medal for Scientific Achievement Lecture. <i>Diabetes</i> , 2021 , 70, 338-346	0.9	6
326	Insulin Resistance Is Associated With Enhanced Brain Glucose Uptake During Euglycemic Hyperinsulinemia: A Large-Scale PET Cohort. <i>Diabetes Care</i> , 2021 , 44, 788-794	14.6	7
325	Effect of Dapagliflozin on Urine Metabolome in Patients with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, 1269-1283	5.6	6
324	Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye?. <i>Diabetes Care</i> , 2021 , 44, 641-646	14.6	4
323	New Insights on the Interactions Between Insulin Clearance and the Main Glucose Homeostasis Mechanisms. <i>Diabetes Care</i> , 2021 , 44, 2115-2123	14.6	5
322	Metabolomic correlates of coronary atherosclerosis, cardiovascular risk, both or neither. Results of the 2 \times phenotypic CAPIRE study. <i>International Journal of Cardiology</i> , 2021 , 336, 14-21	3.2	1
321	Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 2632-2642	6.7	2

320	Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Diabetes and Endocrinology</i> , 2021 , 9, 502-514	18.1	10
319	Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence. <i>Cardiovascular Diabetology</i> , 2021 , 20, 196	8.7	3
318	Insulin enhances renal glucose excretion: relation to insulin sensitivity and sodium-glucose cotransport. <i>BMJ Open Diabetes Research and Care</i> , 2020 , 8,	4.5	5
317	Effects of Sustained Treatment With Lixisenatide on Gastric Emptying and Postprandial Glucose Metabolism in Type 2 Diabetes: A Randomized Controlled Trial. <i>Diabetes Care</i> , 2020 , 43, 1813-1821	14.6	11
316	Brain substrate metabolism and βcell function in humans: A positron emission tomography study. <i>Endocrinology, Diabetes and Metabolism</i> , 2020 , 3, e00136	2.7	4
315	Mechanisms of Sodium-Glucose Cotransporter 2 Inhibition: Insights From Large-Scale Proteomics. <i>Diabetes Care</i> , 2020 , 43, 2183-2189	14.6	11
314	New American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) guidelines for the pharmacotherapy of type 2 diabetes: Placing them into a practicing physician's perspective. <i>Metabolism: Clinical and Experimental</i> , 2020 , 107, 154218	12.7	5
313	Fixed-dose combination of empagliflozin and linagliptin for the treatment of patients with type 2 diabetes mellitus: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1001-1005	6.7	3
312	Brain free fatty acid uptake is elevated in morbid obesity, and is irreversible 6 months after bariatric surgery: A positron emission tomography study. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1074-1082	6.7	11
311	Coronary Artery Disease and Type 2 Diabetes: A Proteomic Study. <i>Diabetes Care</i> , 2020 , 43, 843-851	14.6	12
310	Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea. <i>Endocrinology and Metabolism</i> , 2020 , 35, 329-338	3.5	6
309	SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid-base balance: secondary analysis of a clinical trial reaching glycemic equipoise: Tubular effects of SGLT2 inhibition in Type 2 diabetes. <i>Clinical Science</i> , 2020 , 134, 3107-3118	6.5	4
308	Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 393-403	6.7	30
307	Hormone-substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active-controlled DURATION-8 study. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 99-106	6.7	3
306	Anti-inflammatory properties of antidiabetic drugs: A "promised land" in the COVID-19 era?. <i>Journal of Diabetes and Its Complications</i> , 2020 , 34, 107723	3.2	27
305	Liver nucleotide biosynthesis is linked to protection from vascular complications in individuals with long-term type 1 diabetes. <i>Scientific Reports</i> , 2020 , 10, 11561	4.9	2
304	Association of artificially sweetened and sugar-sweetened soft drinks with βcell function, insulin sensitivity, and type 2 diabetes: the Maastricht Study. <i>European Journal of Nutrition</i> , 2020 , 59, 1717-1727	5.2	4
303	Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial. <i>Diabetes Care</i> , 2019 , 42, e42-e44	14.6	16

302	International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors. <i>Diabetes Care</i> , 2019 , 42, 1147-1154	14.6	138
301	Brain glucose uptake is associated with endogenous glucose production in obese patients before and after bariatric surgery and predicts metabolic outcome at follow-up. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 218-226	6.7	17
300	Renal hemodynamics and fatty acid uptake: effects of obesity and weight loss. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2019 , 317, E871-E878	6	12
299	Quantification of d-mannose in plasma: Development and validation of a reliable and accurate HPLC-MS-MS method. <i>Clinica Chimica Acta</i> , 2019 , 493, 31-35	6.2	4
298	Spontaneous ketonuria and risk of incident diabetes: a 12-year prospective study. <i>Diabetologia</i> , 2019 , 62, 779-788	10.3	5
297	The diabetes pandemic and associated infections: suggestions for clinical microbiology. <i>Reviews in Medical Microbiology</i> , 2019 , 30, 1-17	1.1	61
296	Prospective associations of dietary carbohydrate, fat, and protein intake with Ecell function in the CODAM study. <i>European Journal of Nutrition</i> , 2019 , 58, 597-608	5.2	5
295	Prediction of clamp-derived insulin sensitivity from the oral glucose insulin sensitivity index. <i>Diabetologia</i> , 2018 , 61, 1135-1141	10.3	32
294	Overview of Glucose Homeostasis. <i>Endocrinology</i> , 2018 , 1-23	0.1	
293	Sleeping oxygen saturation, rapid eye movement sleep, and the adaptation of postprandial metabolic function in insulin sensitive and resistant individuals without diabetes. <i>Physiology and Behavior</i> , 2018 , 191, 123-130	3.5	1
292	Hypertension and Diabetes Mellitus: Coprediction and Time Trajectories. <i>Hypertension</i> , 2018 , 71, 422-428	8.5	76
291	Elevated Plasma Levels of 3-Hydroxyisobutyric Acid Are Associated With Incident Type 2 Diabetes. <i>EBioMedicine</i> , 2018 , 27, 151-155	8.8	30
290	High density lipoprotein with apolipoprotein C-III is associated with carotid intima-media thickness among generally healthy individuals. <i>Atherosclerosis</i> , 2018 , 269, 92-99	3.1	8
289	Slope of change in HbA _{1c} from baseline with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes. <i>Endocrinology, Diabetes and Metabolism</i> , 2018 , 1, e00016	2.7	5
288	Insulin resistance and cardiovascular outcomes in the ORIGIN trial. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 564-570	6.7	6
287	Triglyceride-rich very low-density lipoproteins (VLDL) are independently associated with insulin secretion in a multiethnic cohort of adolescents. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2905-2910	6.7	8
286	Effects of acute NEFA manipulation on incretin-induced insulin secretion in participants with and without type 2 diabetes. <i>Diabetologia</i> , 2018 , 61, 1829-1837	10.3	7
285	Short Course of Insulin Treatment versus Metformin in Newly Diagnosed Patients with Type 2 Diabetes. <i>Journal of Clinical Medicine</i> , 2018 , 7,	5.1	3

284	Identification, pathophysiology, and clinical implications of primary insulin hypersecretion in nondiabetic adults and adolescents. <i>JCI Insight</i> , 2018 , 3,	9.9	53
283	Defective Amplifying Pathway of β Cell Secretory Response to Glucose in Type 2 Diabetes: Integrated Modeling of In Vitro and In Vivo Evidence. <i>Diabetes</i> , 2018 , 67, 496-506	0.9	17
282	How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial. <i>Diabetes Care</i> , 2018 , 41, 356-363	14.6	365
281	Overview of Glucose Homeostasis. <i>Endocrinology</i> , 2018 , 1-22	0.1	
280	Metabolomic Profile Predicts Development of Microalbuminuria in Individuals with Type 1 Diabetes. <i>Scientific Reports</i> , 2018 , 8, 13853	4.9	30
279	Adipose tissue and skeletal muscle insulin-mediated glucose uptake in insulin resistance: role of blood flow and diabetes. <i>American Journal of Clinical Nutrition</i> , 2018 , 108, 749-758	7	31
278	microRNA-205-5p is a modulator of insulin sensitivity that inhibits FOXO function. <i>Molecular Metabolism</i> , 2018 , 17, 49-60	8.8	17
277	Insulin resistance and normal thyroid hormone levels: prospective study and metabolomic analysis. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2017 , 312, E429-E436	6	18
276	Fatty acid uptake and blood flow in adipose tissue compartments of morbidly obese subjects with or without type 2 diabetes: effects of bariatric surgery. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2017 , 313, E175-E182	6	20
275	Sodium-glucose co-transporter (SGLT)2 and SGLT1 renal expression in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 1289-1294	6.7	52
274	Sodium-Glucose Co-transporters and Their Inhibition: Clinical Physiology. <i>Cell Metabolism</i> , 2017 , 26, 27-38	14.6	152
273	Effect of exenatide on postprandial glucose fluxes, lipolysis, and β cell function in non-diabetic, morbidly obese patients. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 412-420	6.7	12
272	Mechanisms linking empagliflozin to cardiovascular and renal protection. <i>International Journal of Cardiology</i> , 2017 , 241, 450-456	3.2	24
271	Renal Handling of Ketones in Response to Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2017 , 40, 771-776	14.6	93
270	Discriminatory ability of simple OGTT-based beta cell function indices for prediction of prediabetes and type 2 diabetes: the CODAM study. <i>Diabetologia</i> , 2017 , 60, 432-441	10.3	26
269	Therapy: SGLT inhibition in T1DM - definite benefit with manageable risk. <i>Nature Reviews Endocrinology</i> , 2017 , 13, 698-699	15.2	4
268	Diabetes Research and Care Through the Ages. <i>Diabetes Care</i> , 2017 , 40, 1302-1313	14.6	7
267	Muscle and adipose tissue morphology, insulin sensitivity and beta-cell function in diabetic and nondiabetic obese patients: effects of bariatric surgery. <i>Scientific Reports</i> , 2017 , 7, 9007	4.9	42

266	Plasma Mannose Levels Are Associated with Incident Type 2 Diabetes and Cardiovascular Disease. <i>Cell Metabolism</i> , 2017 , 26, 281-283	24.6	56
265	GLP-1 response to sequential mixed meals: influence of insulin resistance. <i>Clinical Science</i> , 2017 , 131, 2901-2910	6.5	8
264	Associations of Dietary Glucose, Fructose, and Sucrose with β Cell Function, Insulin Sensitivity, and Type 2 Diabetes in the Maastricht Study. <i>Nutrients</i> , 2017 , 9,	6.7	7
263	Regulation of Intermediary Metabolism During Fasting and Feeding 2016 , 598-626.e3		2
262	Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum. <i>Diabetes Care</i> , 2016 , 39, 1186-201	14.6	86
261	Risk Factors for Spontaneously Self-Reported Postprandial Hypoglycemia After Bariatric Surgery. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 3600-3607	5.6	23
260	Impact of a mild decrease in fasting plasma glucose on β cell function in healthy subjects and patients with type 2 diabetes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2016 , 310, E919-24	6	5
259	Integrated Network Analysis Reveals an Association between Plasma Mannose Levels and Insulin Resistance. <i>Cell Metabolism</i> , 2016 , 24, 172-84	24.6	105
258	CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. <i>Diabetes Care</i> , 2016 , 39, 1108-14	14.6	573
257	Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes. <i>Diabetes</i> , 2016 , 65, 1190-5	0.9	327
256	A "systems medicine" approach to the study of non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2016 , 48, 333-42	3.3	42
255	Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes. <i>Diabetologia</i> , 2016 , 59, 700-8	10.3	14
254	Prediction of Declining Renal Function and Albuminuria in Patients With Type 2 Diabetes by Metabolomics. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 696-704	5.6	43
253	Response to Comment on Ferrannini et al. CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. <i>Diabetes Care</i> 2016;39:1108-1114. <i>Diabetes Care</i> , 2016 , 39, e226	14.6	4
252	Response to Comment on Ferrannini et al. <i>Diabetes Care</i> 2016;39:1108-1114. Comment on Mudaliar et al. <i>Diabetes Care</i> 2016;39:1115-1122. <i>Diabetes Care</i> , 2016 , 39, e196-e197	14.6	3
251	β -Hydroxybutyric Acid Is a Selective Metabolite Biomarker of Impaired Glucose Tolerance. <i>Diabetes Care</i> , 2016 , 39, 988-95	14.6	59
250	Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition. <i>Diabetes Care</i> , 2015 , 38, 1730-5	14.6	203
249	Influence of endogenous NEFA on beta cell function in humans. <i>Diabetologia</i> , 2015 , 58, 2344-51	10.3	21

248	Adaptation of β Cell and Endothelial Function to Carbohydrate Loading: Influence of Insulin Resistance. <i>Diabetes</i> , 2015 , 64, 2550-9	0.9	8
247	A novel insulin resistance index to monitor changes in insulin sensitivity and glucose tolerance: the ACT NOW study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 1855-62	5.6	16
246	Epidemiology and geography of type 2 diabetes mellitus 2015 , 29-51		0
245	Epidemiology and risk factors for type 1 diabetes mellitus 2015 , 17-28		2
244	Classification of diabetes mellitus and other categories of glucose intolerance 2015 , 1-16		11
243	Pathology of human diabetic neuropathy 2015 , 926-938		
242	Peripheral vascular and cerebrovascular disease in diabetes mellitus 2015 , 1091-1101		
241	Autonomic neuropathy 2015 , 939-952		
240	Erectile dysfunction in diabetes mellitus 2015 , 975-987		
239	Diabetic retinopathy and other ocular complications 2015 , 889-910		1
238	Clinical features and treatment of coronary heart disease in diabetes 2015 , 1064-1078		1
237	Periodontal disease and diabetes mellitus 2015 , 988-1004		
236	The economics of diabetes care: a global perspective 2015 , 1113-1124		4
235	Arterial hypertension in diabetes: etiology and treatment 2015 , 1079-1090		1
234	Hemostatic abnormalities in diabetes mellitus 2015 , 1051-1063		0
233	Connective tissue disorders in diabetes 2015 , 953-963		3
232	The diabetes challenge: from human and social rights to the empowerment of people with diabetes 2015 , 1103-1112		
231	Atherogenesis, coronary heart disease and insulin resistance syndrome in diabetes 2015 , 1031-1045		

- 230 Epidemiology of macrovascular disease and hypertension in diabetes mellitus **2015**, 1005-1030 3
- 229 Endothelial function and metabolic syndrome **2015**, 1046-1050
- 228 Treatment of obesity: bariatric surgery **2015**, 505-518 1
- 227 Pancreas and islet transplantation **2015**, 774-782
- 226 Glycated hemoglobin, serum proteins, and other markers as tools for monitoring **2015**, 853-871 1
- 225 Pathogenesis of diabetic microvascular complications **2015**, 873-888
- 224 Hypoglycemia and other complications of insulin therapy **2015**, 783-798
- 223 Psychological problems and management of patients with diabetes mellitus **2015**, 846-852
- 222 Type 2 diabetes in obese adolescents: pathophysiology and treatment **2015**, 815-822
- 221 Aging and diabetes mellitus **2015**, 836-845 1
- 220 New drugs for the treatment of diabetes mellitus **2015**, 709-725
- 219 Combination therapy in type 2 diabetes mellitus **2015**, 686-708 1
- 218 Diabetic ketoacidosis and hyperosmolar state **2015**, 799-814 3
- 217 Innovative therapies in diabetes: colesevelam and bromocriptine **2015**, 758-764
- 216 Implantable pumps and artificial and bio-artificial pancreas system **2015**, 765-773
- 215 Insulin pumps **2015**, 745-757
- 214 Incretin-based therapies **2015**, 726-744
- 213 PPAR agonists in the treatment of diabetes **2015**, 657-672

212	α-Glucosidase inhibitors 2015 , 673-685	8
211	Sulfonylureas and meglitinides: insights into physiology and translational clinical utility 2015 , 615-640	2
210	Metformin and other biguanides: pharmacology and therapeutic usage 2015 , 641-656	2
209	Prevention of diabetic microvascular complications 2015 , 564-573	
208	Treatment of obesity: lifestyle and pharmacotherapy 2015 , 489-504	
207	Animal models of obesity and type 2 diabetes 2015 , 519-528	
206	The role of the hypothalamus in the maintenance of energy balance and peripheral glucose control 2015 , 529-537	
205	Prevention of type 1 diabetes 2015 , 539-549	
204	Prevention of type 2 diabetes 2015 , 550-563	
203	Dietary management of diabetes mellitus in Europe and North America 2015 , 575-588	
202	The role of energy metabolism in the regulation of energy balance 2015 , 479-488	
201	The relationship between obesity and type 2 diabetes—the role of gut factors 2015 , 467-478	
200	Pathogenesis of type 2 diabetes mellitus 2015 , 371-400	2
199	Cell mass and function in human type 2 diabetes 2015 , 354-370	3
198	Immunopathogenesis of type 1 diabetes in Western society 2015 , 442-453	0
197	Molecular genetics of type 1 diabetes 2015 , 454-466	
196	Monogenic disorders of the β-cell 2015 , 426-441	
195	Glucose toxicity 2015 , 413-425	3

194	The genetics of type 2 diabetes 2015 , 401-412	
193	The insulin resistance syndrome 2015 , 337-353	0
192	Diabetes and sleep apnea 2015 , 316-336	7
191	Type 2 diabetes and cancer 2015 , 306-315	
190	Treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) 2015 , 292-305	1
189	Pathogenesis of nonalcoholic fatty liver disease (NAFLD) 2015 , 281-291	1
188	Mechanisms of insulin signal transduction 2015 , 161-192	1
187	Metabolomics: applications in type 2 diabetes mellitus and insulin resistance 2015 , 275-280	0
186	Insulin actions in vivo: glucose metabolism 2015 , 211-233	5
185	Lipid and lipoprotein metabolism, hypolipidemic agents, and therapeutic goals 2015 , 262-274	
184	Measuring insulin action in vivo 2015 , 234-249	
183	Protein metabolism in health and diabetes 2015 , 250-261	0
182	Regulation of glucose metabolism in liver 2015 , 193-210	1
181	Incretin physiology in health and disease 2015 , 145-159	
180	Biosynthesis, secretion, and action of glucagon 2015 , 136-144	
179	Neuropeptides and islet hormone secretion 2015 , 125-135	
178	Normal β cell function 2015 , 108-124	2
177	β Cell biology of insulin secretion 2015 , 96-107	1

176	Insulin gene expression and biosynthesis 2015 , 82-95		1
175	Pancreatic morphology in normal and diabetic states 2015 , 69-81		1
174	Development and maintenance of the islet β -cell 2015 , 53-68		1
173	Of microbes and men. <i>Diabetes Care</i> , 2015 , 38, 1817-9	14.6	3
172	Mechanisms through which a small protein and lipid preload improves glucose tolerance. <i>Diabetologia</i> , 2015 , 58, 2503-12	10.3	30
171	Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors. <i>Diabetes Care</i> , 2015 , 38, 1638-42	14.6	419
170	The past 10 years-new hormones, new functions, new endocrine organs. <i>Nature Reviews Endocrinology</i> , 2015 , 11, 681-6	15.2	10
169	Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> , 2015 , 38, 140-9	14.6	1906
168	A novel test for IGT utilizing metabolite markers of glucose tolerance. <i>Journal of Diabetes Science and Technology</i> , 2015 , 9, 69-76	4.1	33
167	Type 2 diabetes mellitus. <i>Nature Reviews Disease Primers</i> , 2015 , 1, 15019	51.1	651
166	Vaccinations and Type 1 Diabetes 2015 , 283-290		
165	Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. <i>European Heart Journal</i> , 2015 , 36, 2288-96	9.5	178
164	Increased Bile Acid Synthesis and Deconjugation After Biliopancreatic Diversion. <i>Diabetes</i> , 2015 , 64, 3377-85	6.85	55
163	Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetologia</i> , 2015 , 58, 429-42	10.3	496
162	New genetic loci link adipose and insulin biology to body fat distribution. <i>Nature</i> , 2015 , 518, 187-196	50.4	920
161	Genetic studies of body mass index yield new insights for obesity biology. <i>Nature</i> , 2015 , 518, 197-206	50.4	2687
160	Identifying glucose thresholds for incident diabetes by physiological analysis: a mathematical solution. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2015 , 308, R590-6	3.2	2
159	Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes. <i>Diabetologia</i> , 2014 , 57, 891-901	10.3	79

158	Residual macrovascular risk in 2013: what have we learned?. <i>Cardiovascular Diabetology</i> , 2014 , 13, 26	8.7	124
157	Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. <i>Autoimmunity Reviews</i> , 2014 , 13, 272-306	3.6	324
156	Extra-ocular muscle cells from patients with Graves Ophthalmopathy secrete CXCL10 and CCL2 chemokines under the influence of cytokines that are modulated by PPAR. <i>Autoimmunity Reviews</i> , 2014 , 13, 1160-6	13.6	20
155	Cell function, incretin effect, and incretin hormones in obese youth along the span of glucose tolerance from normal to prediabetes to type 2 diabetes. <i>Diabetes</i> , 2014 , 63, 3846-55	0.9	60
154	Cell function in type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2014 , 63, 1217-27	12.7	92
153	The threshold shift paradigm of obesity: evidence from surgically induced weight loss. <i>American Journal of Clinical Nutrition</i> , 2014 , 100, 996-1002	7	21
152	The target of metformin in type 2 diabetes. <i>New England Journal of Medicine</i> , 2014 , 371, 1547-8	59.2	83
151	Defining the role of common variation in the genomic and biological architecture of adult human height. <i>Nature Genetics</i> , 2014 , 46, 1173-86	36.3	1339
150	Altered pattern of the incretin effect as assessed by modelling in individuals with glucose tolerance ranging from normal to diabetic. <i>Diabetologia</i> , 2014 , 57, 1199-203	10.3	39
149	CXCR3, CXCL10 and type 1 diabetes. <i>Cytokine and Growth Factor Reviews</i> , 2014 , 25, 57-65	17.9	76
148	Definition of intervention points in prediabetes. <i>Lancet Diabetes and Endocrinology</i> , 2014 , 2, 667-75	18.1	44
147	Common genetic variants highlight the role of insulin resistance and body fat distribution in type 2 diabetes, independent of obesity. <i>Diabetes</i> , 2014 , 63, 4378-4387	0.9	127
146	Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. <i>Journal of Clinical Investigation</i> , 2014 , 124, 499-508	15.9	702
145	Hepatitis C virus infection and type 1 and type 2 diabetes mellitus. <i>World Journal of Diabetes</i> , 2014 , 5, 586-600	4.7	66
144	Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors Expert Forum. <i>Diabetes Care</i> , 2013 , 36, 1779-88	14.6	114
143	Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 2013 , 27, 268-73	3.2	68
142	Antibodies recognizing specific Mycobacterium avium subsp. paratuberculosis MAP3738c protein in type 1 diabetes mellitus children are associated with serum Th1 (CXCL10) chemokine. <i>Cytokine</i> , 2013 , 61, 337-9	4	15
141	Early metabolic markers of the development of dysglycemia and type 2 diabetes and their physiological significance. <i>Diabetes</i> , 2013 , 62, 1730-7	0.9	242

140	Parental history of type 2 diabetes, TCF7L2 variant and lower insulin secretion are associated with incident hypertension. Data from the DESIR and RISC cohorts. <i>Diabetologia</i> , 2013 , 56, 2414-23	10.3	16
139	Biliopancreatic diversion in nonobese patients with type 2 diabetes: impact and mechanisms. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 2765-73	5.6	54
138	Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes. <i>Diabetes Care</i> , 2013 , 36, 1260-5	14.6	60
137	Insulin sensitivity and carotid intima-media thickness: relationship between insulin sensitivity and cardiovascular risk study. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013 , 33, 1409-17	9.4	36
136	Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. <i>Diabetes Care</i> , 2013 , 36, 4015-21	14.6	159
135	Long-term effects of bariatric surgery on meal disposal and β cell function in diabetic and nondiabetic patients. <i>Diabetes</i> , 2013 , 62, 3709-17	0.9	81
134	Influence of apolipoproteins on the association between lipids and insulin sensitivity: a cross-sectional analysis of the RISC Study. <i>Diabetes Care</i> , 2013 , 36, 4125-31	14.6	12
133	Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study. <i>Journal of the American Geriatrics Society</i> , 2013 , 61, 1253-61	5.6	51
132	Mechanisms of the incretin effect in subjects with normal glucose tolerance and patients with type 2 diabetes. <i>PLoS ONE</i> , 2013 , 8, e73154	3.7	29
131	Sweetened beverages intake, hyperuricemia and metabolic syndrome: the Mexico City Diabetes Study. <i>Salud Publica De Mexico</i> , 2013 , 55, 557-63	1.7	9
130	Diabetes and hypertension: the bad companions. <i>Lancet, The</i> , 2012 , 380, 601-10	40	335
129	SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. <i>Nature Reviews Endocrinology</i> , 2012 , 8, 495-502	15.2	283
128	Estimation of prehepatic insulin secretion: comparison between standardized C-peptide and insulin kinetic models. <i>Metabolism: Clinical and Experimental</i> , 2012 , 61, 434-43	12.7	17
127	Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 2818-26	5.6	75
126	Variable modulation by cytokines and thiazolidinediones of the prototype Th1 chemokine CXCL10 in anaplastic thyroid cancer. <i>Cytokine</i> , 2012 , 59, 218-22	4	21
125	Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> , 2012 , 35, 1364-79	14.6	2713
124	Physiology of glucose homeostasis and insulin therapy in type 1 and type 2 diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2012 , 41, 25-39	5.5	18
123	Pathophysiology: Loss of β Cell Function 2012 , 11-29		

122	Pathophysiology of prediabetes. <i>Medical Clinics of North America</i> , 2011 , 95, 327-39, vii-viii	7	98
121	Circulating chemokine (CXC motif) ligand (CXCL)9 is increased in aggressive chronic autoimmune thyroiditis, in association with CXCL10. <i>Cytokine</i> , 2011 , 55, 288-93	4	44
120	Influence of hyperinsulinemia and insulin resistance on in vivo β cell function: their role in human β cell dysfunction. <i>Diabetes</i> , 2011 , 60, 3141-7	0.9	36
119	Cytokines (interferon- γ and tumor necrosis factor- β) induced nuclear factor- κ B activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone. <i>Metabolism: Clinical and Experimental</i> , 2011 , 60, 277-83	12.7	28
118	Peroxisome proliferator-activated receptor β agonists modulate Th1 and Th2 chemokine secretion in normal thyrocytes and Graves disease. <i>Experimental Cell Research</i> , 2011 , 317, 1527-33	4.2	21
117	Improvement in insulin sensitivity and β cell function following ileal interposition with sleeve gastrectomy in type 2 diabetic patients: potential mechanisms. <i>Journal of Gastrointestinal Surgery</i> , 2011 , 15, 1344-53	3.3	45
116	Increase of circulating CXCL9 and CXCL11 associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, 1859-63	5.6	46
115	Body weight, not insulin sensitivity or secretion, may predict spontaneous weight changes in nondiabetic and prediabetic subjects: the RISC study. <i>Diabetes</i> , 2011 , 60, 1938-45	0.9	19
114	Learning from glycosuria. <i>Diabetes</i> , 2011 , 60, 695-6	0.9	26
113	Progression to diabetes in relatives of type 1 diabetic patients: mechanisms and mode of onset. <i>Diabetes</i> , 2010 , 59, 679-85	0.9	100
112	CXCL9 and CXCL11 chemokines modulation by peroxisome proliferator-activated receptor- α agonists secretion in Graves disease and normal thyrocytes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, E413-20	5.6	53
111	alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. <i>PLoS ONE</i> , 2010 , 5, e10883	3.7	469
110	Fatty acid metabolism in the liver, measured by positron emission tomography, is increased in obese individuals. <i>Gastroenterology</i> , 2010 , 139, 846-56, 856.e1-6	13.3	111
109	Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. <i>Diabetes Care</i> , 2010 , 33, 2217-24	14.6	538
108	The stunned beta cell: a brief history. <i>Cell Metabolism</i> , 2010 , 11, 349-52	24.6	128
107	Regulation of Intermediary Metabolism During Fasting and Feeding 2010 , 673-698		5
106	Monokine induced by interferon gamma (IFN γ) (CXCL9) and IFN γ inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor- γ agonists. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 1803-9	5.6	77
105	Impact of different bariatric surgical procedures on insulin action and beta-cell function in type 2 diabetes. <i>Diabetes Care</i> , 2009 , 32, 514-20	14.6	134

104	Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2009 , 297, E225-30	6	20
103	Improved tolerance to sequential glucose loading (Staub-Traugott effect): size and mechanisms. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2009 , 297, E532-7	6	58
102	Insulin resistance versus beta-cell dysfunction in the pathogenesis of type 2 diabetes. <i>Current Diabetes Reports</i> , 2009 , 9, 188-9	5.6	3
101	Thiazolidinediones and antiproliferatives in primary human anaplastic thyroid cancer cells. <i>Clinical Endocrinology</i> , 2009 , 70, 946-53	3.4	58
100	CXCL10 and CCL2 chemokine serum levels in patients with hepatitis C associated with autoimmune thyroiditis. <i>Journal of Interferon and Cytokine Research</i> , 2009 , 29, 345-51	3.5	10
99	Metabolic characteristics of prehypertension: role of classification criteria and gender. <i>Journal of Hypertension</i> , 2009 , 27, 2394-402	1.9	23
98	Primary cell cultures from anaplastic thyroid cancer obtained by fine-needle aspiration used for chemosensitivity tests. <i>Clinical Endocrinology</i> , 2008 , 69, 148-52	3.4	57
97	Alpha-chemokine CXCL10 and beta-chemokine CCL2 serum levels in patients with hepatitis C-associated cryoglobulinemia in the presence or absence of autoimmune thyroiditis. <i>Metabolism: Clinical and Experimental</i> , 2008 , 57, 1270-7	12.7	36
96	Quantification of liver perfusion with [(15)O]H(2)O-PET and its relationship with glucose metabolism and substrate levels. <i>Journal of Hepatology</i> , 2008 , 48, 974-82	13.4	12
95	High values of CXCL10 serum levels in patients with hepatitis C associated mixed cryoglobulinemia in presence or absence of autoimmune thyroiditis. <i>Cytokine</i> , 2008 , 42, 137-43	4	47
94	Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration. <i>European Journal of Endocrinology</i> , 2008 , 159, 283-91	6.5	51
93	Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. <i>Diabetes</i> , 2008 , 57, 1340-8	0.9	297
92	High values of CXCL10 serum levels in mixed cryoglobulinemia associated with hepatitis C infection. <i>American Journal of Gastroenterology</i> , 2008 , 103, 2488-94	0.7	55
91	Early hypertension is associated with reduced regional cardiac function, insulin resistance, epicardial, and visceral fat. <i>Hypertension</i> , 2008 , 51, 282-8	8.5	93
90	Recurrence of cardiovascular events in patients with type 2 diabetes: epidemiology and risk factors. <i>Diabetes Care</i> , 2008 , 31, 2154-9	14.6	59
89	High values of alpha (CXCL10) and beta (CCL2) circulating chemokines in patients with psoriatic arthritis, in presence or absence of autoimmune thyroiditis. <i>Autoimmunity</i> , 2008 , 41, 537-42	3	27
88	Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2008 , 19, 182-7	12.7	107
87	Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 3671-89	5.6	128

86	Th1 and Th2 chemokine serum levels in systemic sclerosis in the presence or absence of autoimmune thyroiditis. <i>Journal of Rheumatology</i> , 2008 , 35, 1809-11	4.1	22
85	Quantification of liver glucose metabolism by positron emission tomography: validation study in pigs. <i>Gastroenterology</i> , 2007 , 132, 531-42	13.3	52
84	Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. <i>Gastroenterology</i> , 2007 , 133, 496-506	13.3	397
83	Common variants of the novel type 2 diabetes genes CDKAL1 and HHEX/IDE are associated with decreased pancreatic beta-cell function. <i>Diabetes</i> , 2007 , 56, 3101-4	0.9	203
82	Beta-cell function in severely obese type 2 diabetic patients: long-term effects of bariatric surgery. <i>Diabetes Care</i> , 2007 , 30, 1002-4	14.6	46
81	Thiazolidinediones improve beta-cell function in type 2 diabetic patients. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007 , 292, E871-83	6	145
80	Insulin resistance, insulin response, and obesity as indicators of metabolic risk. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 2885-92	5.6	131
79	Incidence and risk factors for stroke in type 2 diabetic patients: the DAI study. <i>Stroke</i> , 2007 , 38, 1154-60	6.7	89
78	Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves disease or toxic nodular goiter. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 1485-90	5.6	59
77	Metabolic syndrome: a solution in search of a problem. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 396-8	5.6	63
76	Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. <i>Diabetes Care</i> , 2007 , 30, 1241-7	14.6	123
75	Thyroid cancer in HCV-related chronic hepatitis patients: a case-control study. <i>Thyroid</i> , 2007 , 17, 447-51	6.2	53
74	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). <i>European Heart Journal</i> , 2007 , 28, 88-136	9.5	889
73	Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 614-20	5.6	125
72	Impact of incretin hormones on beta-cell function in subjects with normal or impaired glucose tolerance. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2006 , 291, E1144-50	6	68
71	Increased serum CXCL10 in Graves disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process. <i>European Journal of Endocrinology</i> , 2006 , 154, 651-8	6.5	64
70	The effect of pioglitazone on the liver: role of adiponectin. <i>Diabetes Care</i> , 2006 , 29, 2275-81	14.6	67
69	Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes. <i>Diabetes</i> , 2006 , 55, 1133-40	0.9	146

68	Is insulin resistance atherogenic? A review of the evidence. <i>Atherosclerosis Supplements</i> , 2006 , 7, 5-10	1.7	31
67	Is insulin resistance the cause of the metabolic syndrome?. <i>Annals of Medicine</i> , 2006 , 38, 42-51	1.5	50
66	Increase of CXC chemokine CXCL10 and CC chemokine CCL2 serum levels in normal ageing. <i>Cytokine</i> , 2006 , 34, 32-8	4	64
65	Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves disease, and modulation by methimazole therapy. <i>Clinical Endocrinology</i> , 2006 , 64, 189-95 ³⁻⁴	3.4	57
64	Fasting-based estimates of insulin sensitivity in overweight and obesity: a critical appraisal. <i>Obesity</i> , 2006 , 14, 1250-6	8	26
63	¹⁸ F-FDG assessment of glucose disposal and production rates during fasting and insulin stimulation: a validation study. <i>Journal of Nuclear Medicine</i> , 2006 , 47, 1016-22	8.9	29
62	Differential effect of weight loss on insulin resistance in surgically treated obese patients. <i>American Journal of Medicine</i> , 2005 , 118, 51-7	2.4	109
61	Predictors of weight loss and reversal of comorbidities in malabsorptive bariatric surgery. <i>American Journal of Clinical Nutrition</i> , 2005 , 81, 1292-7	7	50
60	Identification of individuals with insulin resistance using routine clinical measurements. <i>Diabetes</i> , 2005 , 54, 333-9	0.9	270
59	Increase of interferon-gamma inducible alpha chemokine CXCL10 but not beta chemokine CCL2 serum levels in chronic autoimmune thyroiditis. <i>European Journal of Endocrinology</i> , 2005 , 152, 171-7	6.5	69
58	beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 493-500	5.6	407
57	Rosiglitazone treatment increases subcutaneous adipose tissue glucose uptake in parallel with perfusion in patients with type 2 diabetes: a double-blind, randomized study with metformin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 6523-8	5.6	26
56	Increased fat mass compensates for insulin resistance in abdominal obesity and type 2 diabetes: a positron-emitting tomography study. <i>Diabetes</i> , 2005 , 54, 2720-6	0.9	83
55	Hepatitis C virus infection: evidence for an association with type 2 diabetes. <i>Diabetes Care</i> , 2005 , 28, 2548-50	14.6	97
54	beta-cell function in morbidly obese subjects during free living: long-term effects of weight loss. <i>Diabetes</i> , 2005 , 54, 2382-9	0.9	82
53	Beta-cell function in mild type 2 diabetic patients: effects of 6-month glucose lowering with nateglinide. <i>Diabetes Care</i> , 2005 , 28, 1132-8	14.6	22
52	Separate contribution of diabetes, total fat mass, and fat topography to glucose production, gluconeogenesis, and glycogenolysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 3914-21	5.6	88
51	Defective liver disposal of free fatty acids in patients with impaired glucose tolerance. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 3496-502	5.6	29

50	High levels of circulating CXC chemokine ligand 10 are associated with chronic autoimmune thyroiditis and hypothyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 5496-9	5.6	98
49	Visceral fat in hypertension: influence on insulin resistance and beta-cell function. <i>Hypertension</i> , 2004 , 44, 127-33	8.5	196
48	Mode of onset of type 2 diabetes from normal or impaired glucose tolerance. <i>Diabetes</i> , 2004 , 53, 160-5	0.9	112
47	Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. <i>Diabetes Care</i> , 2004 , 27, 1349-57	14.6	152
46	beta-cell function in obesity: effects of weight loss. <i>Diabetes</i> , 2004 , 53 Suppl 3, S26-33	0.9	101
45	Effect of PPAR-gamma activation and inhibition on glucose-stimulated insulin release in INS-1e cells. <i>Diabetes</i> , 2004 , 53 Suppl 3, S79-83	0.9	29
44	Insulin-mediated hepatic glucose uptake is impaired in type 2 diabetes: evidence for a relationship with glycemic control. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 2055-60	5.6	60
43	Influence of ethnicity and familial diabetes on glucose tolerance and insulin action: a physiological analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 3251-7	5.6	36
42	Liver uptake of free fatty acids in vivo in humans as determined with 14(R,S)-[18F]fluoro-6-thia-heptadecanoic acid and PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003 , 30, 1160-4	8.8	20
41	Regional myocardial blood flow and glucose utilization during fasting and physiological hyperinsulinemia in humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2002 , 282, E1163-71	6	44
40	Effect of acute hyperglycemia on insulin secretion in humans. <i>Diabetes</i> , 2002 , 51 Suppl 1, S130-3	0.9	69
39	Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance. <i>Diabetes</i> , 2002 , 51, 3020-4	0.9	127
38	Insulin resistance in morbid obesity: reversal with intramyocellular fat depletion. <i>Diabetes</i> , 2002 , 51, 144-51	0.9	424
37	Meal and oral glucose tests for assessment of beta-cell function: modeling analysis in normal subjects. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2002 , 283, E1159-66	6	235
36	Assessing insulin secretion by modeling in multiple-meal tests: role of potentiation. <i>Diabetes</i> , 2002 , 51 Suppl 1, S221-6	0.9	184
35	Hyperinsulinemia and autonomic nervous system dysfunction in obesity: effects of weight loss. <i>Circulation</i> , 2001 , 103, 513-9	16.7	179
34	Dose-response characteristics of insulin action on glucose metabolism: a non-steady-state approach. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2000 , 278, E794-801	6	73
33	Insulin prolongs the QTc interval in humans. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2000 , 279, R2022-5	3.2	54

32	Effect of vitamin C on forearm blood flow and glucose metabolism in essential hypertension. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000 , 20, 2401-6	9.4	21
31	Independent influence of age on basal insulin secretion in nondiabetic humans. European Group for the Study of Insulin Resistance. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 863-8	5.6	175
30	Autonomic and hemodynamic responses to insulin in lean and obese humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998 , 83, 2084-90	5.6	102
29	Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. <i>Endocrine Reviews</i> , 1998 , 19, 477-90	27.2	325
28	How to measure insulin sensitivity. <i>Journal of Hypertension</i> , 1998 , 16, 895-906	1.9	331
27	Metabolic and cardiovascular assessment in moderate obesity: effect of weight loss. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997 , 82, 2937-43	5.6	47
26	Insulin resistance is central to the burden of diabetes. <i>Diabetes/metabolism Reviews</i> , 1997 , 13, 81-6		46
25	Insulin sensitivity, vascular reactivity, and clamp-induced vasodilatation in essential hypertension. <i>Circulation</i> , 1997 , 96, 849-55	16.7	48
24	Insulin resistance, hyperinsulinemia, and blood pressure: role of age and obesity. European Group for the Study of Insulin Resistance (EGIR). <i>Hypertension</i> , 1997 , 30, 1144-9	8.5	196
23	Insulin resistance is central to the burden of diabetes 1997 , 13, 81		3
22	Effect of insulin on renal sodium and uric acid handling in essential hypertension. <i>American Journal of Hypertension</i> , 1996 , 9, 746-52	2.3	192
21	In vivo effect of insulin on intracellular calcium concentrations: relation to insulin resistance. <i>Metabolism: Clinical and Experimental</i> , 1996 , 45, 1402-7	12.7	27
20	Effect of insulin on acetylcholine-induced vasodilation in normotensive subjects and patients with essential hypertension. <i>Circulation</i> , 1995 , 92, 2911-8	16.7	109
19	Insulin resistance of stress: sites and mechanisms. <i>Clinical Science</i> , 1993 , 85, 525-35	6.5	48
18	Insulin sensitivity in familial hypercholesterolemia. <i>Metabolism: Clinical and Experimental</i> , 1993 , 42, 1359-64	1.4	16
17	The haemodynamics of obesity: a theoretical analysis. <i>Journal of Hypertension</i> , 1992 , 10, 1417-23	1.9	34
16	The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and noninsulin-dependent diabetes mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1991 , 72, 96-107	5.6	280
15	Coronary hemodynamics and myocardial metabolism in patients with syndrome X: response to pacing stress. <i>Journal of the American College of Cardiology</i> , 1991 , 17, 1461-70	15.1	181

14	Hepatic glucose production in insulin-resistant states. <i>Diabetes/metabolism Reviews</i> , 1989 , 5, 711-26		53
13	Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. <i>Metabolism: Clinical and Experimental</i> , 1989 , 38, 387-95	12.7	451
12	Differential effects of insulin and hyperglycemia on intracellular glucose disposition in humans. <i>Metabolism: Clinical and Experimental</i> , 1989 , 38, 459-65	12.7	28
11	Metabolic basis of obesity and noninsulin-dependent diabetes mellitus. <i>Diabetes/metabolism Reviews</i> , 1988 , 4, 727-47		104
10	The disposal of an oral glucose load in patients with non-insulin-dependent diabetes. <i>Metabolism: Clinical and Experimental</i> , 1988 , 37, 79-85	12.7	235
9	The theoretical bases of indirect calorimetry: a review. <i>Metabolism: Clinical and Experimental</i> , 1988 , 37, 287-301	12.7	1251
8	Inadvertent catheterization of the internal thoracic vein mimicking pulmonary embolism: a case report. <i>Journal of Parenteral and Enteral Nutrition</i> , 1988 , 12, 221-2	4.2	11
7	The kinetics of insulin in man. I. General aspects. <i>Diabetes/metabolism Reviews</i> , 1987 , 3, 335-63		67
6	The kinetics of insulin in man. II. Role of the liver. <i>Diabetes/metabolism Reviews</i> , 1987 , 3, 365-97		90
5	Regulation of hepatic glucose metabolism in humans. <i>Diabetes/metabolism Reviews</i> , 1987 , 3, 415-59		122
4	Insulin resistance in essential hypertension. <i>New England Journal of Medicine</i> , 1987 , 317, 350-7	59.2	2068
3	Effect of bicycle exercise on insulin absorption and subcutaneous blood flow in the normal subject. <i>Clinical Physiology</i> , 1982 , 2, 59-70		30
2	The role of fractional glucose extraction in the regulation of splanchnic glucose metabolism in normal and diabetic man. <i>Metabolism: Clinical and Experimental</i> , 1980 , 29, 28-35	12.7	109
1	Lack of a gastrointestinal mediator of insulin action in maturity-onset diabetes. <i>Lancet, The</i> , 1978 , 2, 1074-9		28